Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05633888
Other study ID # PTL015
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 14, 2022
Est. completion date January 2026

Study information

Verified date March 2024
Source Tenon Medical
Contact Calvin Lincé
Phone (510)274-7483
Email clince@linceconsulting.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the outcomes of patients with sacroiliac joint pain treated with the CATAMARAN SI Joint Fusion System.


Description:

This is a multi-center post-market study to evaluate the clinical outcomes of patients with sacroiliac joint disruptions or degenerative sacroiliitis treated with the CATAMARAN SI Joint Fusion System.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date January 2026
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Diagnosis of sacroiliac joint disruption or degenerative sacroiliitis based on ALL of the following: - Patient has pain at or close to the posterior superior iliac spine (PSIS) with possible radiation into buttocks, posterior thigh or groin and can point with a single finger to the location of pain (Fortin Finger Test), and - Patient has at least 3 of 5 physical examination maneuvers specific for SI joint pain (Fabers, Compression, Distraction,Thigh thrust, Gaenslen's test, and/or Sacral thrust test), and - Patient has improvement in lower back pain VAS of at least 50% of the pre injection VAS after fluoroscopic controlled injection of local anesthetic into affected SI joint(s) (including previous documented test <6 months ago) - Patient has failed conservative care (non-surgical) > 6 months - Patient has a pre-operative Oswestry Disability Index score > 30% - Patient has a pre-operative SI joint pain score of > 50 on a 0-100 mm visual analog scale (VAS) - Patient, or authorized representative, signs a written Informed Consent form to participate in the study - Patient is willing and able to complete study follow-up requirements Exclusion Criteria: - Planned bi-lateral SI joint fixation - Severe lower back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture (this is done by physical exam, medical history, and MRI/CT/X-ray as required) - Other known sacroiliac pathology such as: sacral dysplasia, inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA- associated spondyloarthropathy), tumor, acute fracture, crystal arthropathy - History of recent (<1 year) fracture of the pelvis with documented malunion, non-union of sacrum or ilium or any type of internal fixation of the pelvic ring - Severe osteoporosis - Paget's disease, osteomalacia, osteomalacia or other metabolic bone disease - Any condition or anatomy that makes treatment with the CATAMARAN SI Joint Fusion System infeasible including deformity - Known allergy to titanium or titanium alloys - Morbid obesity - Active malignancy: a history of any invasive malignancy (except non-melanoma skin cancer), unless the subject has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least five years - Patient has systemic infection or active infection at the treatment site - Chronic rheumatologic condition (e.g., rheumatoid arthritis) - Patient has uncontrolled diabetes - Patient is currently receiving or seeking worker's compensation, disability remuneration, and/or involved in injury litigation - Prominent neurologic condition that would interfere with physical therapy - Patient is pregnant or wishes to become pregnant in the next two years - Patient is not likely to comply with the follow-up evaluation schedule - Patient is participating in a clinical trial of another investigational drug or device in which the primary endpoint has not occurred - Patient has a psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation - Known or suspected drug or alcohol abuse - Patient is a prisoner or a ward of the state

Study Design


Intervention

Device:
CATAMARAN SI Joint Fusion System
Placement of the Catamaran Fixation Device

Locations

Country Name City State
United States St. Louis Pain Consultants Chesterfield Missouri
United States Northwest Specialty Hospital Coeur d'Alene Idaho
United States Orthopedic Associates of Duluth Duluth Minnesota
United States Vitality Pain Centers Louisville Kentucky
United States Comprehensive Pain and Spine Specialists Muncie Indiana
United States St. George Orthopedic Spine Saint George Utah

Sponsors (1)

Lead Sponsor Collaborator
Tenon Medical

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects that meet the definition of Subject Success at 6 months post-procedure Change from baseline in VAS SI joint pain score to be reduced by at least 20 mm, Lack of device-related serious adverse events, Absence of neurologic worsening related to the sacral spine compared to baseline (unless attributable to a concurrent medical condition or other cause unrelated to the device and/ or study procedure), and Absence of surgical re-intervention (removal, revision, reoperation, or supplemental fixation) for SI joint pain. 6 months post procedure
See also
  Status Clinical Trial Phase
Completed NCT01681004 - Investigation of Sacroiliac Fusion Treatment (INSITE) N/A
Completed NCT02270203 - LOIS: Long-Term Follow-Up in INSITE/SIFI
Enrolling by invitation NCT05628142 - Tenon Medical CATAMARAN™ SI Joint Fusion System CT Scan Study N/A
Active, not recruiting NCT04062630 - SI Joint Stabilization in Long Fusion to the Pelvis N/A
Active, not recruiting NCT01640353 - Sacroiliac Joint Fusion With iFuse Implant System (SIFI) Phase 4